Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : UK variant of COVID-19 is now most common strain in United States - CDC

04/07/2021 | 11:51am EDT

WASHINGTON, April 7 (Reuters) - The highly contagious variant of COVID-19 first discovered in the United Kingdom has become the most common strain of the virus in the United States as cases continue to climb, a top U.S. health official said on Wednesday.

The strain, known as B.1.1.7, was identified in Britain last fall and has since been detected in 52 jurisdictions in the United States, U.S. Centers for Disease Control and Prevention Director Dr. Rochelle Walensky told reporters at a White House briefing.

U.S. public health officials have urged Americans to get vaccinated as soon as possible in part to prevent new variants of the novel coronavirus from spreading.

The United States has also detected cases of a variant first discovered in South Africa that is thought to be resistant to some COVID-19 vaccines and treatments. That strain has been found in 36 U.S. jurisdictions, according to federal data last updated on Tuesday.

The United States is administering about 3 million COVID-19 vaccine doses per day on average over the past week, up 8% over the previous seven-day average, Walensky said.

Vaccine supply has increased significantly in the United States in recent weeks as Johnson & Johnson has begun making millions of doses of its recently authorized shots. Pfizer/BioNTech and Moderna have also recently boosted their vaccine production capacity.

U.S. President Joe Biden has doubled his goal for shots administered in his first 100 days in office from 100 million to 200 million and urged states to begin giving shots to all adults by mid-April. (Open https://tmsnrt.rs/3tUM8ta in an external browser to see a vaccination graphic)

Still, daily U.S. cases of novel coronavirus are averaging 63,000 over the past seven days, up 2.3% from the previous seven-day average, Walensky said.

Walensky said that the CDC has identified a number of COVID-19 outbreaks tied to youth sporting events and that communities experiencing high case counts should avoid holding such events. Testing should also happen twice a week, she said.

White House COVID-19 adviser Andy Slavitt also told reporters that the U.S. government is expanding its community health center program, which it set up in recent weeks to help get vaccines into underserved communities.

(Open https://tmsnrt.rs/34pvUyi in an external browser to see a graphic of global COVID cases and deaths)

(Reporting by Susan Heavey, Jeff Mason and Carl O'Donnell; Editing by Lisa Shumaker)

© Reuters 2021
All news about MODERNA, INC.
02:42pMODERNA  : U.S. administers 189.7 mln doses of COVID-19 vaccines - CDC
02:05pMODERNA  : U.S. CDC Says Delivered 237,796,305 Doses Of Covid-19 Vaccine As Of A..
12:29pTHE LATEST : CDC head warns against surging shots to Michigan
12:18pPFIZER  : Tweaked COVID vaccines in testing aim to fend off variants
08:36aMODERNA  : Canada set to receive 1M Pfizer-BioNTech doses, Moderna playing catch..
08:00aSpain expects first batch of single-dose Janssen shot within 48 hours
04:50aLABORATORIOS FARMACEUTICOS ROVI S A  : Spain's Rovi to Manufacture Active Ingred..
04:30aSpanish drugmaker Rovi to make ingredients for Moderna COVID-19 vaccine
03:41aMODERNA  : Rovi to make active agents for Moderna COVID-19 vaccine
03:01aTAKE FIVE : Who's afraid of U.S. inflation?
More news
Financials (USD)
Sales 2021 17 037 M - -
Net income 2021 8 992 M - -
Net cash 2021 11 953 M - -
P/E ratio 2021 6,43x
Yield 2021 -
Capitalization 56 442 M 56 442 M -
EV / Sales 2021 2,61x
EV / Sales 2022 2,73x
Nbr of Employees 1 300
Free-Float 89,0%
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 166,21 $
Last Close Price 140,92 $
Spread / Highest target 47,6%
Spread / Average Target 17,9%
Spread / Lowest Target -43,2%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.34.89%56 442
LONZA GROUP AG-3.59%43 993
CELLTRION, INC.-13.79%37 705
SEAGEN INC.-18.44%25 900